{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T16:00:27Z","timestamp":1781798427372,"version":"3.54.5"},"publisher-location":"New York, NY","reference-count":16,"publisher":"Springer New York","isbn-type":[{"value":"9781493933884","type":"print"},{"value":"9781493933891","type":"electronic"}],"license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016]]},"DOI":"10.1007\/978-1-4939-3389-1_23","type":"book-chapter","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T11:22:46Z","timestamp":1460632966000},"page":"329-349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Vaccine Design: Replication-Defective Adenovirus Vectors"],"prefix":"10.1007","author":[{"given":"Xiangyang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegund C. J.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,14]]},"reference":[{"key":"23_CR1","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1006\/viro.1996.0239","volume":"219","author":"ZQ Xiang","year":"1996","unstructured":"Xiang ZQ, Yang Y, Wilson JM, Ertl HC (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219:220\u2013227","journal-title":"Virology"},{"key":"23_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.virol.2013.12.029","volume":"450\u2013451","author":"ZQ Xiang","year":"2014","unstructured":"Xiang ZQ, Greenberg L, Ertl HC (2014) Rupprecht CE (2014) Protection of non-human primates against rabies with an adenovirus recombinant vaccine. Virology 450\u2013451:243\u2013249","journal-title":"Virology"},{"key":"23_CR3","doi-asserted-by":"publisher","first-page":"115ra2","DOI":"10.1126\/scitranslmed.3002925","volume":"4","author":"S Colloca","year":"2012","unstructured":"Colloca S, Barnes E, Folgori A et al (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4:115ra2","journal-title":"Sci Transl Med"},{"key":"23_CR4","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2010.10.037","volume":"29","author":"JE Ledgerwood","year":"2010","unstructured":"Ledgerwood JE, Costner P, Desai N, VRC 205 Study Team (2010) A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29:304\u2013313","journal-title":"Vaccine"},{"key":"23_CR5","first-page":"135","volume":"7","author":"PP Hung","year":"1988","unstructured":"Hung PP, Morin JE, Lubeck MD et al (1988) Expression of HBV surface antigen or HIV envelope protein using recombinant adenovirus vectors. Nat Immun Cell Growth Regul 7:135\u2013143","journal-title":"Nat Immun Cell Growth Regul"},{"key":"23_CR6","doi-asserted-by":"publisher","first-page":"6011","DOI":"10.1016\/j.vaccine.2009.07.073","volume":"27","author":"S Khanam","year":"2009","unstructured":"Khanam S, Pilankatta R, Khanna N, Swaminathan S (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27:6011\u20136021","journal-title":"Vaccine"},{"key":"23_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/1743-422X-9-215","volume":"9","author":"BS Shim","year":"2012","unstructured":"Shim BS, Stadler K, Nguyen HH et al (2012) Sublingual immunization with recombinant adenovirus encoding SARS-CoV spike protein induces systemic and mucosal immunity without redirection of the virus to the brain. Virol J 9:215","journal-title":"Virol J"},{"key":"23_CR8","doi-asserted-by":"publisher","first-page":"5761","DOI":"10.1016\/j.vaccine.2014.08.049","volume":"32","author":"A Sharma","year":"2014","unstructured":"Sharma A, Wendland R, Sung B et al (2014) Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection. Vaccine 32:5761\u20135768","journal-title":"Vaccine"},{"key":"23_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3892\/ijmm.2013.1421","volume":"32","author":"K Li","year":"2013","unstructured":"Li K, Li PY, Wu XA et al (2013) Induction of Hantaan virus-specific immune responses in C57BL\/6 mice by immunization with a modified recombinant adenovirus containing the chimeric gene, GcS0.7. Int J Mol Med 32:709\u2013716","journal-title":"Int J Mol Med"},{"key":"23_CR10","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.3892\/or.2013.2950","volume":"31","author":"Y Wang","year":"2014","unstructured":"Wang Y, Liu C, Xia Q et al (2014) Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep 31:1437\u20131444","journal-title":"Oncol Rep"},{"key":"23_CR11","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1089\/hum.2013.103","volume":"25","author":"L Aurisicchio","year":"2014","unstructured":"Aurisicchio L, Peruzzi D, Koo G et al (2014) Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2\/neu in preclinical models. Hum Gene Ther 25:121\u2013131","journal-title":"Hum Gene Ther"},{"key":"23_CR12","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.4049\/jimmunol.1300555","volume":"191","author":"SR Pedersen","year":"2013","unstructured":"Pedersen SR, S\u00f8rensen MR, Buus S et al (2013) Comparison of vaccine-induced effector CD8 T cell responses directed against self- and non-self-tumor antigens: implications for cancer immunotherapy. J Immunol 191:3955\u20133967","journal-title":"J Immunol"},{"key":"23_CR13","doi-asserted-by":"publisher","first-page":"7375","DOI":"10.1158\/1078-0432.CCR-09-1910","volume":"15","author":"DM Lubaroff","year":"2009","unstructured":"Lubaroff DM, Konety BR, Link B et al (2009) Phase I clinical trial of an adenovirus\/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res 15:7375\u20137380","journal-title":"Clin Cancer Res"},{"key":"23_CR14","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/415331a","volume":"415","author":"JW Shiver","year":"2002","unstructured":"Shiver JW, Fu TM, Chen L et al (2002) Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331\u2013335","journal-title":"Nature"},{"key":"23_CR15","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1182\/blood-2007-02-062117","volume":"110","author":"N Tatsis","year":"2007","unstructured":"Tatsis N, Fitzgerald JC, Reyes-Sandoval A et al (2007) Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110:1916\u20131923","journal-title":"Blood"},{"key":"23_CR16","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/nprot.2010.134","volume":"5","author":"D Zhou","year":"2010","unstructured":"Zhou D, Zhou X, Bian A et al (2010) An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5:1775\u20131785","journal-title":"Nat Protoc"}],"container-title":["Methods in Molecular Biology","Vaccine Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-3389-1_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T02:05:04Z","timestamp":1605233104000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-3389-1_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"ISBN":["9781493933884","9781493933891"],"references-count":16,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-3389-1_23","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"14 April 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}